Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

JOURNAL ARTICLE published August 2015 in The Lancet Oncology

Authors: Antoni Ribas | Igor Puzanov | Reinhard Dummer | Dirk Schadendorf | Omid Hamid | Caroline Robert | F Stephen Hodi | Jacob Schachter | Anna C Pavlick | Karl D Lewis | Lee D Cranmer | Christian U Blank | Steven J O'Day | Paolo A Ascierto | April K S Salama | Kim A Margolin | Carmen Loquai | Thomas K Eigentler | Tara C Gangadhar | Matteo S Carlino | Sanjiv S Agarwala | Stergios J Moschos | Jeffrey A Sosman | Simone M Goldinger | Ronnie Shapira-Frommer | Rene Gonzalez | John M Kirkwood | Jedd D Wolchok | Alexander Eggermont | Xiaoyun Nicole Li | Wei Zhou | Adriane M Zernhelt | Joy Lis | Scot Ebbinghaus | S Peter Kang | Adil Daud